Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
How to buy Stoke Therapeutics stock
Learn how to easily invest in Stoke Therapeutics stock.
Stoke Therapeutics is a biotechnology business based in the US. Stoke Therapeutics shares (STOK) are listed on the NASDAQ and all prices are listed in US Dollars. Stoke Therapeutics employs 117 staff and has a trailing 12-month revenue of around $12.4 million.
How to buy Stoke Therapeutics stock
- Choose a stock trading platform. Use our comparison table or choose from our Top Picks below.
- Open an account. Provide your personal information and sign up.
- Fund your account. Deposit funds unto your account by linking your banking information or transfer funds from another trading account.
- Search for the stock name – STOK. Search for the stock by name or ticker symbol.
- Buy the stock. Place your order. It's that simple.
- Trade stocks for $0 and no annual fee
- Start trading with a $0 minimum deposit
- Get up to $1,000 when you fund a new account within 30 days
- Easy to use platform with $0 stock trading & no annual fees
- Social trading allows you to copy popular portfolios
- FINDER EXCLUSIVE: Guaranteed $15 bonus when you sign up and deposit $100
- $0 commissions on stocks and ETFs
- $0 closing commissions on stock and ETF options
- Get $100 - $2,000 when you open and fund an account with $5,000 to $100,000+
Stoke Therapeutics stock price (NASDAQ: STOK)Use our graph to track the performance of STOK stocks over time.
Stoke Therapeutics shares at a glance
|Latest market close||$8.17|
|52-week range||$6.88 - $26.00|
|50-day moving average||$9.21|
|200-day moving average||$12.08|
|Wall St. target price||$31.64|
|Dividend yield||$0 (0%)|
|Earnings per share (TTM)||$-2.60|
Buy Stoke Therapeutics stocks from these online trading platformsCompare special offers, low fees and a wide range of investment options among top trading platforms.
Information on this page is for educational purposes only. Finder is not an advisor or brokerage service, and we don't recommend investors to trade specific stocks or other investments.
Finder is not a client of any featured partner. We may be paid a fee for referring prospective clients to a partner, though it is not a recommendation to invest in any one partner.
Is it a good time to buy Stoke Therapeutics stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Stoke Therapeutics price performance over time
Historical closes compared with the close of $8.17 from 2023-03-20
|1 week (2023-03-15)||-10.71%|
|1 month (2023-02-22)||-7.58%|
|3 months (2022-12-22)||-3.20%|
|6 months (2022-09-22)||-45.17%|
|1 year (2022-03-22)||-67.23%|
|2 years (2021-03-22)||-82.69%|
|3 years (2020-03-20)||22.21|
|5 years (2018-03-18)||N/A|
Stoke Therapeutics financials
|Revenue TTM||$12.4 million|
|Gross profit TTM||$12.4 million|
|Return on assets TTM||-26.36%|
|Return on equity TTM||-50.2%|
|Market capitalisation||$404 million|
TTM: trailing 12 months
Stoke Therapeutics share dividends
We're not expecting Stoke Therapeutics to pay a dividend over the next 12 months.
Have Stoke Therapeutics's shares ever split?
Stoke Therapeutics's shares were split on a 1:9 basis on 5 June 2019. So if you had owned 9 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Stoke Therapeutics shares – just the quantity. However, indirectly, the new 800% higher share price could have impacted the market appetite for Stoke Therapeutics shares which in turn could have impacted Stoke Therapeutics's share price.
Stoke Therapeutics share price volatility
Over the last 12 months, Stoke Therapeutics's shares have ranged in value from as little as $6.88 up to $26. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Stoke Therapeutics's is 0.4207. This would suggest that Stoke Therapeutics's shares are less volatile than average (for this exchange).
Stoke Therapeutics overview
Stoke Therapeutics, Inc. , an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels. Its lead clinical candidate is STK-002, which is in preclinical stage for the treatment of autosomal dominant optic atrophy. The company is also developing STK-001, which is in phase I/II clinical trial to treat Dravet syndrome; and programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye. It had entered into a license and collaboration agreement with Acadia Pharmaceuticals Inc. for the discovery, development, and commercialization of novel RNA-based medicines for the treatment of severe and rare genetic neurodevelopmental diseases of the central nervous system.
Stoke Therapeutics in the news
Stoke Therapeutics Announces That FDA Will Allow the Administration of a Higher Single Dose of STK-001 (70mg) in the Ongoing Phase 1/2a MONARCH Study of Children and Adolescents with Dravet Syndrome
Stoke Therapeutics, Inc. (STOK) Reports Q4 Loss, Tops Revenue Estimates
Stoke Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Updates
Frequently asked questionsWhat percentage of Stoke Therapeutics is owned by insiders or institutions?
Currently 5.585% of Stoke Therapeutics shares are held by insiders and 91.804% by institutions. How many people work for Stoke Therapeutics?
Latest data suggests 117 work at Stoke Therapeutics. When does the fiscal year end for Stoke Therapeutics?
Stoke Therapeutics's fiscal year ends in December. Where is Stoke Therapeutics based?
Stoke Therapeutics's address is: 45 Wiggins Avenue, Bedford, MA, United States, 01730 What is Stoke Therapeutics's ISIN number?
Stoke Therapeutics's international securities identification number is: US86150R1077 What is Stoke Therapeutics's CUSIP number?
Stoke Therapeutics's Committee on Uniform Securities Identification Procedures number is: 86150R107
More guides on Finder
How to Buy Treasury Bills
Treasury Bills are fixed-income assets with maturities of less than one year. Here’s what to know before investing.
How to buy Vanguard VTI Total Stock Market ETF units
Steps to investing in the Vanguard (VTI) Total Stock Market ETF.
How to buy Neuraxis (NRXS) stock when it goes public
Everything we know about the Neuraxis IPO, plus information on how to buy in.
How to buy TXO Energy (TXO) stock
Everything we know about the TXO Energy IPO, plus information on how to buy in.
How to buy Brera (BREA) stock
Everything we know about the Brera IPO, plus information on how to buy in.
How to invest in the S&P 500
What you need to know about investing in the leading indicator for the overall US stock market.
How to buy IPO stock
Buying an IPO is as simple as buying any other stock, but not every trading platform offers IPO stocks.
How to buy Novo Integrated Sciences stock
Steps to owning and managing NVOS, with 24-hour and historical pricing before you buy.
How do ETFs work?
Your simple and straightforward guide to ETFs, how they work and the different types available.
What is stock lending?
Find out how stock lending works, the extra income you could potentially earn and the risks you should be aware of. Plus, compare stock trading platforms that offer stock lending.
Ask an Expert